This association was found to be maintained in breast cancer patients, correlating the expression of IL8 and TGF-β with diminished patient prognosis, making these findings of great clinical importance and highlighting the potential benefit of TGF-β inhibitors in combination with conventional chemotherapy [194]. The gene discussed is CXCL8; the disease is breast carcinoma.